Drug intelligence / Profile preview

haloperidol + quetiapine + risperidone

Development stage: Preclinical
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

A combination of three antipsychotic medications: haloperidol (a first-generation/typical antipsychotic), quetiapine (a second-generation/atypical antipsychotic), and risperidone (a second-generation/atypical antipsychotic). This combination provides multiple mechanisms of action targeting various neurotransmitter systems, primarily through dopamine and serotonin receptor antagonism. The combination may be used in treatment-resistant cases of psychotic disorders or for controlling aggression and hostility in acute psychotic episodes.

Targets

HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on haloperidol + quetiapine + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + quetiapine + risperidone.

Explore the full profile